ArticleJournal of physiology and biochemistry2015
A signature of microRNA-155 in the pathogenesis of diabetic complications.
Article in Journal of physiology and biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.Journal of nephrology · 2018Pooled it
- Exploring the role of microRNA-155 as a biomarker and regulatory modulator of target genes in metabolic syndrome.SAGE open medicine · 2026Review
- Exploring the role of miRNA in diabetic neuropathy: from diagnostics to therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.International journal of molecular sciences · 2021Review
- Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients.International journal of molecular sciences · 2021Article
- Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy.Frontiers in neurology · 2020Review
- Gene polymorphism and plasma levels of miR-155 in diabetic retinopathy.Endocrine connections · 2019Article
- Impact of Diabetes Mellitus on Bone Health.International journal of molecular sciences · 2019Review
- microRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammation.Scientific reports · 2019Article
- The diagnostic value of circulating microRNAs in heart failure.Experimental and therapeutic medicine · 2019Review
- Protein S Protects against Podocyte Injury in Diabetic Nephropathy.Journal of the American Society of Nephrology : JASN · 2018Article
- Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.Scientific reports · 2017Article
- Polydatin impairs mitochondria fitness and ameliorates podocyte injury by suppressing Drp1 expression.Journal of cellular physiology · 2017Article
- MiR-3202 - Promoted H5V Cell Apoptosis by Directly Targeting Fas Apoptotic Inhibitory Molecule 2 (FAIM2) in High Glucose Condition.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Characterization of extracellular vesicles derived from cardiac cells in anJournal of extracellular vesicles · 2017Article
- Inhibition of miR-155 Protects Against LPS-induced Cardiac Dysfunction and Apoptosis in Mice.Molecular therapy. Nucleic acids · 2016Article
- MiR-155 Enhances Insulin Sensitivity by Coordinated Regulation of Multiple Genes in Mice.PLoS genetics · 2016Article
- High protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; association with diet/genetics-regulated micro-RNAs.Journal of diabetes & metabolism · 2016Article
- Alteration in Inflammation-related miR-146a Expression in NF-KB Signaling Pathway in Diabetic Rat Hippocampus.Advanced pharmaceutical bulletin · 2016Article
- EXPRESSION PROFILES OF MIR-155-5P AND MIR-518B MICRORNAS IN CIRCULATING LEUKOCYTES OF THE PREGNANT PATIENTS WITH PREECLAMPSIA AND POLYCYSTIC OVARY SYNDROME.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study was designed to explore the potential involvement of miR-155 in the pathogenesis of diabetes complications. Male rats were divided into control and diabetic groups (n = 6). Type 2 diabetes was induced by a single-dose injection of nicotinamide (110 mg/kg; intraperitoneal (i.p.)), 15 min before injection of streptozotocin (STZ; 50 mg/kg; i.p.) in 12-h fasted rats. Two months after induction of diabetes, the rats were sacrificed for subsequent measurements. The nuclear factor kappa B (NF-κB) activity was higher in diabetic peripheral blood mononuclear cells (PBMCs), aorta, heart, kidney, liver, and sciatic nerve, than the control counterparts. Also, apoptosis rate was increased in these tissues, except the aorta. NF-κB messenger RNA (mRNA) expression level was higher in the kidney, heart, PBMCs, and sciatic nerve of diabetic rats than their control counterparts. Except the liver, the miR-155 expression level was significantly decreased in diabetic kidney, heart, aorta, PBMCs, and sciatic nerve versus the controls. Moreover, the expression of miR-155 was negatively correlated with NF-κB activity and apoptosis rate. These results suggest that changes in the expression of miR-155 may participate in the pathogenesis of diabetes-related complications, but causal relationship between miR-155 dysregulation and diabetic complications is unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.